Laura Steele was appointed President and General Manager (GM) of Lilly UK, Ireland, and Northern Europe in July 2021. Laura leads Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. Laura joined the UK from her previous role in Lilly’s Corporate Business Development division in the US, where she specialised in innovation-led partnerships, large-scale projects in M&A, investments and joint ventures to drive growth across the company.
An insightful and authentic leader, Laura is a champion of diversity and inclusion initiatives and is passionate about developing talent and building high-performing teams. Laura’s 18-year career at Lilly spans sales, payer and marketing roles, where she built a reputation for a tenacious approach to innovation and her unfaltering commitment to patient-centricity. Under Laura’s leadership, the company’s Migraine Marketing division in Indianapolis accomplished multiple company and industry firsts, including projects in telemedicine and digital marketing. Laura was awarded the Gold Marketer, 2020 Marketer of the Year by Medical Marketing & Media. Laura has a Bachelor of Science in Business Administration (Villanova University), with a Major in Marketing and Minor in Communications.
Dr Emily Pegg has a decade of experience in the pharmaceutical industry, starting at Novartis, where for 5 years she worked in both UK and regional roles in its Neuroscience franchise. In late 2018, Emily moved to Shire shortly before its acquisition by Takeda, where she was the Country Medical Lead for Genetic Diseases and later Head of Medical Affairs for Oncology.
Most recently, Emily held the role of Associate Medical Director for Takeda UK and Ireland before moving to Lilly in 2023 to take up the role of Associate VP – Medical, Northern European Hub. Prior to her career in the pharmaceutical industry Emily trained as a clinical doctor in the NHS and is a Member of the Faculty of Pharmaceutical Medicine.
Lisa Broad is Associate Vice President, Global Pain Research and Early Development, Eli Lilly and Company. She heads up Lilly’s Neuroscience team in the UK and is also Managing Director of the Lilly UK Research and Development Office.
Lisa is a physiologist/pharmacologist by training with 22 years of industrial experience focused on discovery and development of novel therapeutics in the Neuroscience area.
Prior to joining Lilly, Lisa completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge. Lisa received her doctorate from the University of Cambridge.